Ibn Sina Pharma (S.A.E) operates as a pharmaceutical distributor in Egypt.
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م3.23|
|52 Week High||ج.م2.99|
|52 Week Low||ج.م6.49|
|1 Month Change||-3.58%|
|3 Month Change||-13.17%|
|1 Year Change||-45.53%|
|3 Year Change||-55.50%|
|5 Year Change||n/a|
|Change since IPO||-36.19%|
Recent News & Updates
|ISPH||EG Healthcare||EG Market|
Return vs Industry: ISPH underperformed the EG Healthcare industry which returned -16.1% over the past year.
Return vs Market: ISPH underperformed the EG Market which returned 9.2% over the past year.
Stable Share Price: ISPH is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ISPH's weekly volatility (4%) has been stable over the past year.
About the Company
|2001||n/a||Mohamed Mohsen Mahgoub||https://www.ibnsina-pharma.com|
Ibn Sina Pharma (S.A.E) operates as a pharmaceutical distributor in Egypt. The company offers a portfolio of pharmaceutical and cosmetics products to private and public-sector customers, including retail chains, independent pharmacies, wholesalers, and hospitals and healthcare institutions. It also provides warehousing and logistic services for its suppliers; marketing solutions; and importation and packaging services.
Ibn Sina Pharma Company (S.A.E.) Fundamentals Summary
|ISPH fundamental statistics|
Is ISPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ISPH income statement (TTM)|
|Cost of Revenue||ج.م18.40b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.21|
|Net Profit Margin||0.99%|
How did ISPH perform over the long term?See historical performance and comparison
Is Ibn Sina Pharma Company (S.A.E.) undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ISPH (EGP3.23) is trading above our estimate of fair value (EGP2.14)
Significantly Below Fair Value: ISPH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ISPH is good value based on its PE Ratio (15.7x) compared to the African Healthcare industry average (32.3x).
PE vs Market: ISPH is poor value based on its PE Ratio (15.7x) compared to the EG market (11.6x).
Price to Earnings Growth Ratio
PEG Ratio: ISPH is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: ISPH is good value based on its PB Ratio (2.2x) compared to the XF Healthcare industry average (2.8x).
How is Ibn Sina Pharma Company (S.A.E.) forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ISPH's forecast earnings growth (24.2% per year) is above the savings rate (9.1%).
Earnings vs Market: ISPH's earnings (24.2% per year) are forecast to grow faster than the EG market (14.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ISPH's revenue (15.2% per year) is forecast to grow faster than the EG market (9.9% per year).
High Growth Revenue: ISPH's revenue (15.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ISPH's Return on Equity is forecast to be high in 3 years time (25.4%)
How has Ibn Sina Pharma Company (S.A.E.) performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ISPH has high quality earnings.
Growing Profit Margin: ISPH's current net profit margins (1%) are lower than last year (1.4%).
Past Earnings Growth Analysis
Earnings Trend: ISPH's earnings have grown by 9.8% per year over the past 5 years.
Accelerating Growth: ISPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ISPH had negative earnings growth (-23.5%) over the past year, making it difficult to compare to the Healthcare industry average (4.5%).
Return on Equity
High ROE: ISPH's Return on Equity (16.9%) is considered low.
How is Ibn Sina Pharma Company (S.A.E.)'s financial position?
Financial Position Analysis
Short Term Liabilities: ISPH's short term assets (EGP8.3B) exceed its short term liabilities (EGP7.9B).
Long Term Liabilities: ISPH's short term assets (EGP8.3B) exceed its long term liabilities (EGP511.1M).
Debt to Equity History and Analysis
Debt Level: ISPH's debt to equity ratio (449.2%) is considered high.
Reducing Debt: ISPH's debt to equity ratio has reduced from 658.9% to 449.2% over the past 5 years.
Debt Coverage: ISPH's debt is not well covered by operating cash flow (6.9%).
Interest Coverage: ISPH's interest payments on its debt are not well covered by EBIT (2x coverage).
What is Ibn Sina Pharma Company (S.A.E.) current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ISPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ISPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ISPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ISPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ISPH's dividend in 3 years as they are not forecast to pay a notable one for the EG market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mohamed Mohsen Mahgoub
Mr. Mohamed Mohsen Mohamed Mahgoub serves as Vice Chairman and Chief Executive Officer at Ibn Sina Pharma (S.A.E) since April 2021. He served as Executive Chairman until April 2021 and has been Director at...
Experienced Management: ISPH's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Experienced Board: ISPH's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ibn Sina Pharma Company (S.A.E.)'s employee growth, exchange listings and data sources
- Name: Ibn Sina Pharma Company (S.A.E.)
- Ticker: ISPH
- Exchange: CASE
- Founded: 2001
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: ج.م3.101b
- Shares outstanding: 960.00m
- Website: https://www.ibnsina-pharma.com
Number of Employees
- Ibn Sina Pharma Company (S.A.E.)
- Industrial Zone 1
- El Obour City
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 14:31|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.